B7-H4 Vasculature Expression Analysis for RCC Therapy Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for renal cell carcinoma (RCC) are limited, particularly for metastatic disease, with low survival rates and limited effectiveness of chemotherapy, radiation, and immunotherapy, necessitating the need for additional therapeutic targets.
Innovation Solution
Evaluating B7-H4 expression in the vasculature of tumors to differentiate between patients likely to benefit from IL-2 immunotherapy and identifying B7-H4 as a therapeutic target, using methods such as antibody detection and immunohistochemistry, and delivering agents like antibodies or RNAi to reduce B7-H4 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (chemotherapy, radiation, immunotherapy) are used for metastatic RCC, then treatment options are available, but effectiveness is low and survival rates remain poor
Solution Approach 1:
The patent changes the parameter of therapeutic targeting by shifting from conventional non-specific chemotherapy and radiation to a targeted immunotherapy approach based on B7-H4 expression status. This parameter change enables personalized treatment selection, improving effectiveness by matching patients to therapies most likely to work for their specific tumor biology
Solution Approach 2:
The patent segments the patient population into distinct groups based on B7-H4 expression levels in tumor vasculature. This segmentation allows for tailored treatment strategies: IL-2 immunotherapy for B7-H4 negative patients and alternative therapies for B7-H4 positive patients, thereby improving overall treatment effectiveness across diverse patient populations
2Adaptability or versatility
If IL-2 immunotherapy is administered to all RCC patients, then immunotherapy coverage is maximized, but response rate remains low at less than 10%
Solution Approach 1:
The patent implements preliminary action by assessing B7-H4 expression status in tumor vasculature before initiating IL-2 immunotherapy. This pre-treatment evaluation identifies patients most likely to respond durably to IL-2, allowing clinicians to select appropriate candidates beforehand and avoid administering ineffective therapy to B7-H4 positive patients
Solution Approach 2:
The patent establishes a feedback mechanism where B7-H4 expression status informs treatment selection. By using vasculature B7-H4 levels as a predictive marker, the system provides feedback that guides therapeutic decisions, ensuring patients receive the most effective treatment modality based on their tumor's molecular characteristics
3Measurement precision
If B7-H4 expression is detected in tumor vasculature, then patient classification accuracy improves, but treatment complexity increases due to need for personalized therapy selection
Solution Approach 1:
The patent simplifies treatment protocol complexity by changing the decision-making parameter from multiple clinical factors to a single molecular marker (B7-H4 expression status). This binary classification system (B7-H4 positive vs. negative) provides clear, actionable guidance for treatment selection, reducing the complexity of personalized therapy decisions while maintaining high classification accuracy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach helps classify patients' cancer aggressiveness and potential response to IL-2 therapy, providing a new target for therapy and potentially improving anti-tumor immune responses by reducing B7-H4's inhibitory effects on T-cell function.
Implementation Method 1
Detecting can include contacting the tissue sample with an antibody (e.g., a fluorescently labeled antibody) that binds to B7-H4
Implementation Method 2
Detecting can include fluorescence flow cytometry (FFC)
Implementation Method 3
Detecting can include fluorescence flow cytometry (FFC) or immunohistochemistry
Data Source
AI summary
Methods of evaluating patients by assessing expression of B7-H4 in the vasculature are described.